{
  "id": 1768556905621,
  "title": "Pharmacology of IOP-Lowering Agents: The Comprehensive Guide",
  "summary": "An exhaustive clinical overview of the pharmacological groups used in glaucoma management, detailed mechanism of action, efficacy statistics, and critical safety profiles. This guide highlights the modern shift toward preservative-free therapies and the emergence of novel therapeutic compounds.",
  "date": "2026-01-16T09:48:25.621Z",
  "data": {
    "title": "Pharmacology of IOP-Lowering Agents: The Comprehensive Guide",
    "summary": "An exhaustive clinical overview of the pharmacological groups used in glaucoma management, detailed mechanism of action, efficacy statistics, and critical safety profiles. This guide highlights the modern shift toward preservative-free therapies and the emergence of novel therapeutic compounds.",
    "summary_illustration": "<svg viewBox=\"0 0 100 100\" xmlns=\"http://www.w3.org/2000/svg\"><circle cx=\"50\" cy=\"50\" r=\"40\" fill=\"none\" stroke=\"#1d4ed8\" stroke-width=\"2\"/><path d=\"M30 50 Q50 20 70 50 Q50 80 30 50\" fill=\"#bfdbfe\"/><circle cx=\"50\" cy=\"50\" r=\"12\" fill=\"#1e40af\"/><path d=\"M50 20 V10 M50 90 V80 M20 50 H10 M90 50 H80\" stroke=\"#1d4ed8\" stroke-width=\"2\"/><path d=\"M75 25 L85 15\" stroke=\"#ef4444\" stroke-width=\"3\" marker-end=\"arrow\"/><text x=\"25\" y=\"95\" font-family=\"Arial\" font-size=\"6\" fill=\"#1e40af\">PHARMACOLOGY</text></svg>",
    "sections": [
      {
        "title": "Modern Trends in Glaucoma Therapy",
        "icon": "trending_up",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "blue",
        "content": [
          "In recent years, there has been an increasing awareness of the ocular side effects of preserved glaucoma drugs.",
          "Resulted in an i focus on using preservative-free drop therapy.",
          "Reducing polypharmacy by the use of fixed combination preparations.",
          "Novel compounds are currently under evaluation including: rho kinase inhibitors, adenosine receptor agonists, modified PGAs, and sustained-release intracameral preparations."
        ]
      },
      {
        "title": "Prostaglandin Analogues (PGAs)",
        "icon": "medication",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "green",
        "content": [
          "Mechanism: these analogues of PGF2α increase uveoscleral outflow.",
          "Table 10.6 Data: i IOP by 30%. Well tolerated.",
          "Examples: Latanoprost 0.005% (preservative-free available), travoprost 0.004%, Bimatoprost 0.03% + 0.01% (preservative-free available), tafluprost 0.015% (preservative-free).",
          "Common Ocular Side Effects: conjunctival hyperaemia, i pigmentation of iris (and sometimes lid skin), thickening and lengthening of lashes, loss of orbital fat.",
          "Rare Ocular Side Effects: uveitis, CMO, reactivation of herpetic kerato-uveitis."
        ]
      },
      {
        "title": "PGA Warnings",
        "icon": "warning",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Contraindications: may be associated with CMO after complicated cataract surgery (possibly active uveitis).",
          "Systemic side effects: Bronchospasm (rare)."
        ]
      },
      {
        "title": "Beta-blockers",
        "icon": "heart_broken",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Mechanism: reduce aqueous production, probably by acting on β -receptors on the non-pigmented ciliary epithelium and vasoconstriction of the arterioles supplying ciliary processes.",
          "Table 10.6 Data: 20y follow-up d IOP by ± 25%. Well tolerated (in most cases).",
          "Non-selective Examples: timolol 0.25% + 0.5% (available preservative-free), Carteolol 1% + 2% (has intrinsic sympathomimetic activity), Levobunolol 0.5% (available preservative-free).",
          "β 1-selective Examples: Betaxolol 0.25% + 0.5%.",
          "Ocular side effects: uncommon; allergic blepharoconjunctivitis, punctate keratitis."
        ]
      },
      {
        "title": "Beta-blocker Red Flags & Interactions",
        "icon": "dangerous",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Contraindications: asthma/COPD (bronchospasm may occur, even with selective β 1 agents), heart block, bradycardia, or cardiac failure.",
          "Try to avoid in nursing mothers, as it is secreted in breast milk.",
          "Interaction: cardiac-directed Ca 2+ antagonists (e.g. verapamil) may compound bradycardia, heart block, and hypotension.",
          "Systemic Side Effects: Bronchospasm, Bradycardia, heart block, hypotension, Glucose intolerance, Lethargy, Depression, Impotence."
        ]
      },
      {
        "title": "Carbonic Anhydrase Inhibitors (CAIs)",
        "icon": "science",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "purple",
        "content": [
          "Mechanism: reduce aqueous production by inhibiting carbonic anhydrase isoenzyme II (and hence bicarbonate production) in the non-pigmented ciliary epithelium.",
          "Topical Examples: Brinzolamide 1%, Dorzolamide 2% (preservative-free available).",
          "Topical Efficacy: d IOP by ± 20%.",
          "Systemic Example: Acetazolamide.",
          "Systemic Efficacy: Decrease aqueous production; Acidosis may cause hypotension. d IOP by ≤65%.",
          "Ocular Side Effects: common—burning, tearing, allergic blepharoconjunctivitis (up to 10%); rare—intraocular inflammation."
        ]
      },
      {
        "title": "CAI Contraindications & Interactions",
        "icon": "report_problem",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Contraindications: sulfonamide sensitivity; renal failure, liver failure (systemic acetazolamide).",
          "Drug Interactions: K+ -losing diuretics (e.g. thiazide) may cause profound hypokalaemia if used concurrently with acetazolamide.",
          "Note: K+ supplementation is not usually required for acetazolamide used alone.",
          "Systemic SE (Topical): Metallic taste.",
          "Systemic SE (Systemic): Lethargy, Depression, Anorexia, hypokalaemia, renal calculi, Blood dyscrasia."
        ]
      },
      {
        "title": "Sympathomimetics",
        "icon": "bolt",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "Mechanism: Decrease aqueous production, Increase uveoscleral outflow.",
          "Efficacy: d IOP by ± 20%.",
          "Modern Agents: α2-selective brimonidine 0.2% (well tolerated), apraclonidine 0.5% + 1% (α1 + α2; 1% is preservative-free).",
          "Seldom used (Older agents): adrenaline (epinephrine), dipivefrine, and the adrenergic neurone blocker guanethidine.",
          "Ocular Side Effects: allergic blepharoconjunctivitis (up to 15% for brimonidine, 30% for apraclonidine).",
          "Older Agent Side Effects: scarring, mydriasis, adrenochrome deposits.",
          "Other Side Effects: uncommon—CMO in aphakia (possibly pseudophakia). Intraocular inflammation and iIOP can occur with acute hypersensitivity."
        ]
      },
      {
        "title": "Sympathomimetic Safety",
        "icon": "priority_high",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Contraindications: heart block, bradycardia.",
          "Drug interactions: monoamine oxidase inhibitors.",
          "Systemic side effects: Bradycardia, hypotension, Insomnia, Irritability."
        ]
      },
      {
        "title": "Miotics (Parasympathomimetics)",
        "icon": "visibility",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "green",
        "content": [
          "Mechanism: Muscarinic receptor agonism leads to ciliary muscle contraction, which pulls on the scleral spur to open the trabecular meshwork (Increase trabecular outflow).",
          "Example: Pilocarpine 0.5%–4% (available preservative-free).",
          "Efficacy: d IOP by ± 30%+.",
          "Clinical Use: first line in narrow-angle glaucoma; sometimes still used in POAG. Useful in pigmentary glaucomas, aphakic glaucoma, and some 2° glaucomas (e.g. post-PK).",
          "Ocular side effects: fluctuating myopia, miosis (constricted VF, reduced night vision)."
        ]
      },
      {
        "title": "Miotics & Hyperosmotics",
        "icon": "emergency",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Miotics Contraindications: inflammatory or aqueous misdirection/malignant glaucoma. GI disturbance.",
          "Miotics Systemic SE: Sweating, Sialorrhoea, Nausea, headache, bradycardia.",
          "Hyperosmotic Agents: Mannitol (IV), Glycerol (PO).",
          "Hyperosmotic Mechanism: Creates an osmotic gradient. rapidly d IOP (onset 30min).",
          "Hyperosmotic Systemic SE: hypertension, Vomiting, Cardiac failure, MI, hyperglycaemia (mannitol), Urinary retention."
        ]
      },
      {
        "title": "IOP Reduction Potential by Group",
        "icon": "bar_chart",
        "type": "chart",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "type": "bar",
          "data": [
            {
              "label": "PGAs (30%)",
              "value": 30
            },
            {
              "label": "Beta-blockers (25%)",
              "value": 25
            },
            {
              "label": "CAIs Topical (20%)",
              "value": 20
            },
            {
              "label": "Alpha-2 Agonists (20%)",
              "value": 20
            },
            {
              "label": "Miotics (30%+)",
              "value": 35
            },
            {
              "label": "Systemic CAI (65%)",
              "value": 65
            }
          ]
        }
      },
      {
        "title": "Pharmacological Groups Summary (Table 10.6)",
        "icon": "table_chart",
        "type": "table",
        "layout": "full_width",
        "color_theme": "purple",
        "content": {
          "headers": [
            "Group",
            "Mechanism",
            "Advantages",
            "Systemic Side Effects",
            "Examples"
          ],
          "rows": [
            [
              "PGAs",
              "Increase uveoscleral outflow",
              "i IOP by 30% Well tolerated",
              "Bronchospasm (rare)",
              "Latanoprost 0.005%, Travoprost 0.004%, Bimatoprost 0.03%+0.01%, Tafluprost 0.015%"
            ],
            [
              "β-blocker",
              "Decrease aqueous production",
              "20y follow-up d IOP by ± 25% Well tolerated (in most cases)",
              "Bronchospasm, Bradycardia, heart block, hypotension, Glucose intolerance, Lethargy, Depression, Impotence",
              "Timolol 0.25%+0.5%, Carteolol 1%+2%, Levobunolol 0.5%, Betaxolol 0.25%+0.5%"
            ],
            [
              "Topical CAIs",
              "Decrease aqueous production",
              "d IOP by ± 20%",
              "Metallic taste",
              "Brinzolamide 1%, Dorzolamide 2%"
            ],
            [
              "α2-agonists",
              "Decrease aqueous production, Increase uveoscleral outflow",
              "d IOP by ± 20%",
              "Bradycardia, hypotension, Insomnia, Irritability",
              "Brimonidine 0.2%, Apraclonidine 0.5%+1%"
            ],
            [
              "Miotics",
              "Increase trabecular outflow",
              "d IOP by ± 30%+",
              "Sweating, Sialorrhoea, Nausea, headache, bradycardia",
              "Pilocarpine 0.5%–4%"
            ],
            [
              "Systemic CAI",
              "Decrease aqueous production",
              "d IOP by ≤65%",
              "Acidosis (may cause hypotension), Lethargy, Depression, Anorexia, hypokalaemia, renal calculi, Blood dyscrasia",
              "Acetazolamide"
            ],
            [
              "Hyperosmotics",
              "Creates an osmotic gradient",
              "rapidly d IOP (onset 30min)",
              "hypertension, Vomiting, Cardiac failure, MI, hyperglycaemia (mannitol), Urinary retention",
              "Mannitol (IV), Glycerol (PO)"
            ]
          ]
        }
      },
      {
        "title": "Additional Reference Information",
        "icon": "info",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "Ph A r MACOLOG y OF IOP- LOW er ING AG e N t S 419. Ch AP ter 10 Glaucoma 420. the major drug groups are summarized in table 10.6. apraclonidine (α1 + α2) is useful for short-term use, e.g. after laser iridotomy."
      }
    ]
  },
  "chapterId": "glaucoma",
  "communityId": "sub_1768552123966_kjyww2dje",
  "communityAuthor": "Dodi",
  "communityDate": "2026-01-16T08:28:43.966Z",
  "_serverSynced": true,
  "_newlyImported": 1768587692880,
  "seqId": 108
}